Tilray Reports Record $217.5 Million Revenue in Q2 Fiscal 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5h ago
0mins
Source: NASDAQ.COM
- Record Revenue: Tilray's revenue for Q2 fiscal 2026 reached $217.5 million, marking a historic high despite only a 3% year-over-year increase, indicating some resilience in the company's market position.
- International Sales Growth: The company saw a 36% rise in international medical cannabis sales, suggesting that Tilray's global expansion strategy is beginning to yield results, although overall growth remains lackluster, reflecting efforts in product line diversification.
- Improved Operating Loss: The operating loss for the quarter was $22.3 million, an improvement from $42.2 million a year ago, primarily due to significant reductions in restructuring costs and amortization expenses, demonstrating effective cost control measures.
- Beverage Segment Decline: Despite overall revenue growth, the beverage segment experienced a 21% decline in sales to $50.1 million, indicating challenges within this business line that could impact the company's future growth potential, prompting investors to closely monitor its long-term strategic direction.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.750
Low
8.50
Averages
9.57
High
10.00
Current: 8.750
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
